Equities

IO Biotech Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IOBT:NSQ

IO Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3555
  • Today's Change-0.012 / -3.16%
  • Shares traded2.60m
  • 1 Year change-62.18%
  • Beta0.4513
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

  • Revenue in USD (TTM)0.00
  • Net income in USD-88.35m
  • Incorporated2021
  • Employees80.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Regentis Biomaterials Ltd0.00-5.20m23.88m-----------1.00-1.000.00-1.870.00-------1,548.81--------------------------226.60------
LAMY0.00106.70k24.50m--25.51--201.80--0.01370.01370.00-0.00450.00------763.23-----------------------67.39--299.15------
Lunai Bioworks Inc0.00-130.98m24.84m29.00---------7.51-7.510.00-0.56260.00----0.00-203.39-75.79-304.47-85.18-----------28.85---------101.31------
Boundless Bio Inc0.00-61.76m25.07m64.00--0.2276-----16.06-16.060.004.920.00----0.00-35.93---38.37--------------0.00-------32.22------
IGC Pharma Inc1.11m-6.45m25.20m70.00--2.99--22.78-0.078-0.0780.01340.0880.110.548926.0215,800.00-64.10-51.04-81.62-56.8846.2043.57-582.82-1,150.020.889--0.0165---5.50-20.7745.22---35.93--
Aeon Biopharma Inc0.00-3.00k25.23m5.000.2156--323.40--4.874.870.00-1.710.00----0.00-0.0471-----------------5.95--------110.92------
Rallybio Corp674.00k-14.17m25.35m15.00--0.3992--37.61-2.55-2.550.120312.020.0092----26,960.00-19.32-40.97-21.16-43.42-----2,102.37-42,838.52----0.00------22.52------
Marker Therapeutics Inc4.69m-14.30m25.84m5.00--1.41--5.50-1.23-1.230.36831.100.2876--3.90938,996.00-87.60-57.72-110.67-69.11-----304.54-761.28----0.00--99.0698.6323.60------
IO Biotech Inc0.00-88.35m26.41m80.00--28.08-----1.34-1.340.000.01310.00----0.00-136.03-58.51-184.96-64.76------------0.9482-------10.93------
Cue Biopharma Inc7.10m-37.68m26.57m41.00--1.98--3.74-0.4553-0.45530.08230.17030.1857--4.01173,170.70-98.58-60.20-170.74-73.56-----530.75-683.99----0.1107--69.1621.8419.83--7.32--
Evaxion A/S (ADR)7.65m-5.42m26.94m46.00------3.52-16.88-16.882.18--------166,326.10---96.54---126.06-----70.88-2,792.25--------4,480.82--52.24------
Exicure Inc0.00-9.23m27.47m8.00--3.97-----3.07-3.070.001.090.00----0.00-71.27-44.45-94.78-60.08-------259.52----0.00-----17.3442.65------
Raphael Pharmaceutical Inc0.00-1.40m27.48m0.00---------0.0723-0.07230.00-0.06440.00-------4,831.04-----------------86.56---------13.02------
Oncotelic Therapeutics Inc0.00-1.67m27.82m26.00--3.06-----0.0041-0.00410.000.02060.00----0.00-7.00-20.78-19.04-43.80-------1,590.30---0.55910.632---100.00--42.76------
Quince Therapeutics Inc0.00-56.98m29.38m36.00--27.15-----1.22-1.220.000.01940.00----0.00-48.20-42.95-55.60-46.33------------0.943-------81.07--36.12--
Data as of Feb 11 2026. Currency figures normalised to IO Biotech Inc's reporting currency: US Dollar USD

Institutional shareholders

36.56%Per cent of shares held by top holders
HolderShares% Held
Lundbeckfond Invest A/Sas of 11 Apr 202513.95m19.39%
HBM Partners AG (Investment Management)as of 31 Dec 20245.52m7.68%
Ikarian Capital LLCas of 30 Sep 20251.53m2.12%
Millennium Management LLCas of 30 Sep 20251.39m1.94%
Marshall Wace LLPas of 30 Sep 20251.05m1.46%
BofA Securities, Inc.as of 30 Sep 2025799.95k1.11%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2025668.40k0.93%
Boothbay Fund Management LLCas of 30 Sep 2025591.18k0.82%
Renaissance Technologies LLCas of 30 Sep 2025547.32k0.76%
Point72 Asset Management LPas of 30 Sep 2025250.00k0.35%
More ▼
Data from 11 Apr 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.